Abstracts Archive - Page 387 of 2425 - ACR Meeting Abstracts

Abstract Number: 1541 • ACR Convergence 2022
MRI Digital Artery Volume Index (DAVIX) Predicts Future Digital Ulcers and Disease Progression in Systemic Sclerosis
Michael Hughes¹, Stefano Di Donato², Klodian Gjeloshi³, Giuseppina Abignano⁴, Fiammetta Danzo³, Giovanni Lettieri G⁴, Enrico De Lorenzis², Dominic Bertham⁵, Philip O’Connor², Olga Kubassova⁶ and Francesco Del Galdo², ¹Department of Rheumatology, Tameside and Glossop Integrated Care NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ³University of Campania ‘‘Luigi Vanvitelli’’, Napoli, Italy, ⁴Istituto Reumatologico Lucano (IReL), Azienda Ospedaliera Regionale San Carlo, Potenza, Italy, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Image Analysis Group, London, United Kingdom
Background/Purpose: Fibroproliferative vasculopathy in systemic sclerosis (SSc) is caused by neointima proliferation is a key pathologic feature of SSc which results in arterial vessel narrowing…
Abstract Number: 1533 • ACR Convergence 2022
Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees
Alexandru Garaiman¹, Carina Mihai¹, Rucsandra Dobrota¹, cosimo bruni², Muriel Elhai¹, Suzana Jordan¹, Lea Stamm³, Anna-Maria Hoffmann-vold⁴, Oliver Distler¹ and Mike Becker¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²University of Florence, Florence, Italy, ³Department of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: Some gastrointestinal (GI) and nutritional factors are associated with the presence of interstitial lung disease related to systemic sclerosis (SSc-ILD). However, there are many…
Abstract Number: 1290 • ACR Convergence 2022
Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage and Patient Distress Are as Prominent in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist
Juan Schmukler¹, Tengfei Li², Joel Block¹ and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Georgetown University, Washington, DC
Background/Purpose: Most widely-used rheumatology indices, e.g., DAS28, CDAI, SLEDAI, ASDAS, DAPSA, reflect the mission of rheumatologists to control inflammatory activity (INF) to prevent subsequent organ…
Abstract Number: 1484 • ACR Convergence 2022
Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients
Megan Zhao¹, Kevin Williams², Douglas Jacoby³, Rui Feng⁴ and Victoria Werth⁵, ¹Perelman School of Medicine, Philadelphia, ²Temple University Hospital System, Philadelphia, ³University of Pennsylvania Health System, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Lupus erythematosus (LE) patients are at heightened risk of clinical events, chiefly heart attacks and strokes, caused by ASCVD. To address this problem, we…
Abstract Number: 1516 • ACR Convergence 2022
How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis
Federico Fattorini¹, Cosimo Cigolini², Gabriele Marchetti³, Andrea Delle Sedie⁴, Linda Carli⁵ and Marta Mosca⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ³University of Pisa, Pisa, Toscana, Italy, ⁴University of Pisa, Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, PISA, Italy
Background/Purpose: Spondyloarthropathies (SpA) may compromise the working ability (WA) of patients, often affected by the disease during their productive life. The Work Productivity and Activity…
Abstract Number: 1529 • ACR Convergence 2022
Clinical Nailfold Capillaroscopy Using Dinolite Microscope in Patients with Systemic Sclerosis
Krishnasai Abhishek Madathanapalli¹, Alyssa Williams², Baran Ilayda Gunes², Francis Perry Wilson³, John Pauling⁴, Robyn Domsic⁵, Lan Yu⁶ and Monique Hinchcliff⁷, ¹University of Connecticut School of Medicine, Hartford, CT, ²Yale University, New Haven, CT, ³Yale school of medicine, New Haven, CT, ⁴North Bristol NHS Trust, Bristol, United Kingdom, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, ⁷Yale School of Medicine, Westport, CT
Background/Purpose: The clinical importance of nailfold capillaroscopy (NFC) has grown since its inclusion in the 2013 ACR/EULAR Classification Criteria for systemic sclerosis (SSc), yet few…
Abstract Number: 1431 • ACR Convergence 2022
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis
Karen E Hansen¹, Mahta Mortezavi², Edward Nagy³, Cunshan Wang⁴, Carol A Connell⁴, Zaher Radi⁵, Heather J Litman⁶, Giovanni Adami⁷ and Maurizio Rossini⁷, ¹Rheumatology Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Pfizer Inc, New York, NY, ³Pfizer Ltd, Tadworth, United Kingdom, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Cambridge, MA, ⁶CorEvitas, LLC, Waltham, MA, ⁷Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Preclinical data suggest that tofacitinib stimulates osteoblast function and would have a protective effect on bone health and fracture risk in RA.1 We report…
Abstract Number: 1493 • ACR Convergence 2022
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Miroslawa Nowak², Jiyoon Choi³, Tom Lehman², Antoine Sreih⁴, Taylor Blachley⁵, Blessing Dube⁵, Kaylee Ho⁵, Nicole Middaugh⁵ and Alexis Ogdie⁶, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴Bristol Myers Squibb, Philadelphia, PA, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…
Abstract Number: 1540 • ACR Convergence 2022
Correlations of Soluble Interleukin-2 Receptor Serum Levels with Markers of Inflammation and Pathological High-sensitivity Troponin T and Its Possible Role as a Predictor of Early Clinical Progress in Systemic Sclerosis
Luise Schumacher¹, Sebastian Klapa², Antje Mueller³ and Gabriela Riemekasten⁴, ¹University of Lübeck, Lübeck, Germany, ²Universityhospital Schleswig-Holstein; University of Lübeck; Clinic of Rheumatology and Clinical Immunology, Luebeck, Germany, ³University Hospital Schleswig-Holstein (UKSH), Lübeck, ⁴University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany
Background/Purpose: Systemic sclerosis (SSc) is characterized by chronic inflammation leading to damage of the vascular endothelium and excessive collagen deposition in several target organs. The…
Abstract Number: 1299 • ACR Convergence 2022
Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children
Jo-Anne Marcuz¹, Brian Feldman², Y. Ingrid Goh³, Niina Kim⁴, Piya Lahiry⁵, Deborah Levy², Elizaveta Limenis⁶, Jeanine McColl⁷, Christine O'Brien⁸, Susan Paetkau⁴, Shirley Tse², Kristi Whitney⁸ and Ronald Laxer², ¹Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children; Department of Pediatrics, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, ⁸Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children with significant morbidity that extends into adulthood. Despite advances in effective…
Abstract Number: 1525 • ACR Convergence 2022
Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey
Sakir Ahmed¹, Naveen R², John Pauling³, Darpan Thakare², Chris Wincup⁴, Nicoletta Del Papa⁵, Gianluca Sambataro⁶, Fabiola Atzeni⁷, SIMONE PARISI⁸, Marcello Govoni⁹, Elena Bartoloni Bocci¹⁰, Gian Domenico Sebastiani¹¹, Enrico Fusaro¹², Marco Sebastiani¹³, Luca Quartuccio¹⁴, Franco Franceschini¹⁵, Pier Paolo Sainaghi¹⁶, Giovanni Orsolini¹⁷, Rossella De Angelis¹⁸, Maria Giovanna Danielli¹⁹, Vincenzo Venerito²⁰, Parikshit Sen²¹, Minchul Kim²², Abraham Edgar Gracia-Ramos²³, Akira Yoshida²⁴, James B. Lilleker²⁵, Vishwesh Agarwal²⁶, Sinan Kardes²⁷, Jessica Day²⁸, Mrudula Joshi²⁹, Marcin Milchert³⁰, Tamer A Gheita³¹, Babur Salim³², Ioannis Parodis³³, Albert Selva O’Callaghan³⁴, Elena Nikiphorou³⁵, Tulika Chatterjee²², Ai Lyn Tan³⁶, Arvind Nune³⁷, Lorenzo Cavagna³⁸, Samuel Shinjo³⁹, Nelly Ziade⁴⁰, Johannes Knitza⁴¹, Hector Chinoy⁴², Oliver Distler⁴³, Masataka Kuwana⁴⁴, Rohit Aggarwal⁴⁵, Latika Gupta⁴⁶, Vikas Agarwal² and Ashima Makol⁴⁷, ¹Kalinga Institute of Medical Sciences, Bhubaneswar, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴University College London, London, United Kingdom, ⁵Unità operativa complessa (UOC) Day Hospital Reumatologia via Gaetano Pini 9, Centro Specialistico Ortopedico Traumatologico, Gaetano Pini-CTO, Milano, Italy, ⁶Medico Immunologia e reumatologia presso, Artoreuma S.R.L., Cors S, Mascalucia, ⁷Rheumatology Unit, University of Messina, Messina, Italy, ⁸Italian Society for Rheumatology, Turin, Italy, ⁹S. Anna Hospital and University of Ferrara, Ferrara, Italy, ¹⁰Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ¹¹U.O.C. Reumatologia, Ospedale San Camillo-Forlanini,, Roma, ¹²Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ¹³Azienda Policlinico di Modena, Modena, Italy, ¹⁴Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy, ¹⁵Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹⁶Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy, ¹⁷Department of Medicine, Rheumatology Unit, University of Verona, Verona, Verona, ¹⁸Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy, ¹⁹Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle, Marche, Italy, ²⁰Department of Emergency and Organ Transplantations-Rheumatology Unit, University of Bari "Aldo Moro", Bari, Italy, ²¹Maulana Azad Medical College, New Delhi, India, ²²University of Illinois College of Medicine Peoria, Peoria, IL, ²³Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ²⁴Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ²⁵The University of Manchester, Manchester, United Kingdom, ²⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ²⁷Istanbul University, Istanbul, Turkey, ²⁸Walter and Eliza Hall Institute, Melbourne, Australia, ²⁹Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ³⁰Pomeranian Medical University in Szczecin, Szczecin, Poland, ³¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ³²Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ³³Karolinska Institutet, Stockholm, Sweden, ³⁴Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³⁵Leiden University Medical Center & King's College London, London, United Kingdom, ³⁶University of Leeds, Leeds, United Kingdom, ³⁷Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ³⁸Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ³⁹Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ⁴⁰Saint-Joseph University, Beirut, Lebanon, ⁴¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴²The University of Manchester, Sale, United Kingdom, ⁴³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴⁴Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴⁶Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ⁴⁷Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (AIRDs) are considered more susceptible to break through infection (BI) following vaccination due to their immunosuppressed status and…
Abstract Number: 1420 • ACR Convergence 2022
Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Dimitrios Pappas¹, Jacqueline O'Brien², Mike Kelleman², Lin Guo², Ying Shan², Joshua Baker³, Greg Kricorian⁴, Scott Stryker⁵ and David Collier⁶, ¹Corrona Research Foundation; CorEvitas, LLC, Albany, NY, ²CorEvitas, LLC, Waltham, MA, ³University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., San Francisco, CA, ⁶Amgen Inc., Simi Valley, CA
Background/Purpose: Biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) often are used as monotherapy in rheumatoid arthritis (RA). However, little is known about the comparative effectiveness of…
Abstract Number: 1536 • ACR Convergence 2022
Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR
Anna-Maria Hoffmann-Vold¹, Cathrine Brunborg¹, Paolo Airò², Lidia P. Ananyeva³, László Czirják⁴, Serena Guiducci⁵, Eric Hachulla⁶, MENGTAO LI⁷, Carina Mihai⁸, Gabriela Riemekasten⁹, Petros P. Sfikakis¹⁰, Gabriele Valentini¹¹, Otylia Kowal-Bielecka¹², Yannick Allanore¹³ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, ³V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁴Medical school of Pécs, Pecs, Hungary, ⁵University of Firenze, Firenze, Italy, ⁶University of Lille, Lille, France, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁹University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, ¹⁰Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ¹¹Università della Campania “Luigi Vanvitelli”, Napoli, Italy, ¹²Medical University of Bialystok, Bialystok, Poland, ¹³Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: Short disease duration is a well known predictor for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD), but studies assessing ILD progression in later disease…
Abstract Number: 1504 • ACR Convergence 2022
Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement
Alexis Ogdie¹, Christopher Ritchlin², Priscila Nakasato³, Ran Liu⁴, Christian Kaufmann⁴, Byron Padilla⁵ and Laure Gossec⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ³AbbVie Inc, Toronto, ON, Canada, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶Sorbonne Université, Paris, France
Background/Purpose: PsA is a systemic disease involving multiple domains. Peripheral joints are frequently affected, and patients often initially present with asymmetrical oligoarthritis (2-4 swollen joints).…
Abstract Number: 1434 • ACR Convergence 2022
Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis
YoungEun Kim¹, Soo Min Ahn¹, Ji Seon Oh², Yong Gil Kim¹, Chang Keun Lee¹, Bin Yoo¹ and Seokchan Hong¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Neutropenia has been reported as one of the most frequent adverse events of tocilizumab. We conducted a retrospective cohort study to determine the risks…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].